Septerna (SEPN) Boosts IPO Size to Raise $275 Million

GuruFocus10-25

Biotechnology firm Septerna has announced an increase in its planned initial public offering (IPO) size. The company now intends to issue 15.3 million shares at $18 each, aiming to raise $275 million....

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2478342929?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-25 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2478342929","market":"hk","top_or_hot":-1,"title":"Septerna (SEPN) Boosts IPO Size to Raise $275 Million","media":"GuruFocus","content":"<div>\n<p>Biotechnology firm Septerna has announced an increase in its planned initial public offering (IPO) size. The company now intends to issue 15.3 million shares at $18 each, aiming to raise $275 million....</p>\n\n<a href=\"https://www.gurufocus.com/news/2567410/septerna-sepn-boosts-ipo-size-to-raise-275-million\">Source Link</a>\n\n</div>\n","source":"gurufocus_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Septerna (SEPN) Boosts IPO Size to Raise $275 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSepterna (SEPN) Boosts IPO Size to Raise $275 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-25 22:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.gurufocus.com/news/2567410/septerna-sepn-boosts-ipo-size-to-raise-275-million><strong>GuruFocus</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biotechnology firm Septerna has announced an increase in its planned initial public offering (IPO) size. The company now intends to issue 15.3 million shares at $18 each, aiming to raise $275 million....</p>\n\n<a href=\"https://www.gurufocus.com/news/2567410/septerna-sepn-boosts-ipo-size-to-raise-275-million\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GPCR","symbol_name":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","start_time":0,"source_url":"https://www.gurufocus.com/news/2567410/septerna-sepn-boosts-ipo-size-to-raise-275-million","article_id":"2478342929","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2478342929","pubTimestamp":1729864896,"sourceInfo":{"source_id":"gurufocus_highlight","name":"GuruFocus"},"weMediaInfo":null,"summary":"Biotechnology firm Septerna has announced an increase in its planned initial public offering  size. The company now intends to issue 15.3 million shares at $18 each, aiming to raise $275 million. This marks an increase from its previous plan to issue 10.9 million shares priced between $15 and $17, targeting $175 million. Septerna will list on Nasdaq under the ticker \"SEPN\".Founded in 2019, Septerna specializes in developing novel oral small molecule drugs targeting the G protein-coupled receptor  class. Its principal clinical-stage project is SEP-786, aimed at treating hypoparathyroidism by targeting the parathyroid hormone 1 receptor . The company is conducting a Phase 1 trial for this treatment in patients with the rare endocrine disorder and expects top-line data by mid-2025.Additionally, Septerna is working on SEP-631, a negative allosteric modulator  of MRGPRX2, intended for the treatment of chronic spontaneous urticaria  and other mast cell diseases. SEP-631 is currently in the i","collect":0,"end_time":0,"defaultTopTitle":"gurufocus.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"GPCR":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","SEPN":"Septerna, Inc.","BK4007":"制药","IPO":"Renaissance IPO ETF"},"translate_title":"Septerna(SEPN)扩大IPO规模，筹集2.75亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GPCR":1,"IPO":1,"SEPN":1},"content_text":"Biotechnology firm Septerna has announced an increase in its planned initial public offering (IPO) size. The company now intends to issue 15.3 million shares at $18 each, aiming to raise $275 million. This marks an increase from its previous plan to issue 10.9 million shares priced between $15 and $17, targeting $175 million. Septerna will list on Nasdaq under the ticker \"SEPN\".Founded in 2019, Septerna specializes in developing novel oral small molecule drugs targeting the G protein-coupled receptor (GPCR) class. Its principal clinical-stage project is SEP-786, aimed at treating hypoparathyroidism by targeting the parathyroid hormone 1 receptor (PTH1R). The company is conducting a Phase 1 trial for this treatment in patients with the rare endocrine disorder and expects top-line data by mid-2025.Additionally, Septerna is working on SEP-631, a negative allosteric modulator (NAM) of MRGPRX2, intended for the treatment of chronic spontaneous urticaria (CSU) and other mast cell diseases. SEP-631 is currently in the investigational new drug (IND) preparation stage. For the 12 months ending June 30, 2024, Septerna reported revenue of $1 million.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2478342929"}